Alprostadil (Caverject/MUSE) Cost in Nebraska 2026

What Does Alprostadil Cost in Nebraska in 2026?

Brand alprostadil costs approximately $600 per month cash-pay at Nebraska retail pharmacies in 2026. That figure covers both Caverject (intracavernosal injection) and MUSE (urethral suppository) formulations at standard starting doses. Generic injectable alprostadil is available but still carries a list price close to the brand because the molecule has limited generic competition in the U.S. market.

The $600 benchmark reflects the Pfizer wholesale acquisition cost passed through most Nebraska pharmacy benefit managers. Actual register prices vary by pharmacy chain and by dose. Caverject Impulse 10 mcg kits (6 syringes) at a Walgreens or Walmart in Omaha or Lincoln typically price between $580 and $640 before any discount card is applied. MUSE 500 mcg suppositories (6 units) track similarly.

Alprostadil is a synthetic prostaglandin E1 analog. It relaxes smooth muscle in the corpus cavernosum, increasing arterial inflow and producing an erection within 5 to 20 minutes of administration. The FDA approved Caverject in 1995 and MUSE in 1996 following a key double-blind trial by Linet and colleagues published in the New England Journal of Medicine. [1] That trial (N=296) showed 64.9% of men achieved at least one successful act of intercourse on alprostadil versus 18.6% on placebo (P<0.001). [1]

The American Urological Association guidelines on erectile dysfunction list alprostadil as a second-line therapy after oral phosphodiesterase-5 inhibitors such as sildenafil and tadalafil. [2] Second-line status means most Nebraska insurers require documented failure of at least one PDE5 inhibitor before approving alprostadil.

GoodRx and similar discount platforms consistently list Nebraska retail prices for Caverject between $560 and $620 depending on the specific pack configuration. [3] Applying a GoodRx coupon at a Nebraska pharmacy typically saves 5 to 15 percent off the shelf price, which still leaves most patients paying over $500 monthly. [3]

Does Nebraska Medicaid Cover Alprostadil?

Nebraska Medicaid does not cover alprostadil for erectile dysfunction. The Nebraska Department of Health and Human Services pharmacy benefit excludes drugs prescribed primarily for sexual dysfunction, consistent with the federal Medicaid exclusion categories under 42 U.S.C. § 1396r-8. [4] Patients enrolled in Nebraska Heritage Health (the managed Medicaid program) face the same exclusion regardless of which managed care organization administers their plan.

Some Nebraska Medicaid members with a non-erectile-dysfunction diagnosis, such as pulmonary arterial hypertension or peripheral vascular disease, may qualify for coverage of prostaglandin E1 agents under a different indication code. That is a narrow exception and requires explicit prior authorization with supporting clinical documentation from a vascular specialist or pulmonologist.

Nebraska's Medicaid expansion under the Affordable Care Act, which took effect October 2020, extended coverage to adults earning up to 138% of the federal poverty level. [5] Expansion improved access to many medications, but the sexual dysfunction exclusion remained intact. Patients who obtained Medicaid through expansion and need alprostadil for ED must pay out of pocket or pursue compounded alternatives.

Is Compounded Alprostadil Legal in Nebraska?

Compounded alprostadil is legal in Nebraska when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. Nebraska follows federal USP standards and the Drug Quality and Security Act framework that governs 503A compounding pharmacies. [6] A prescriber licensed in Nebraska, including a telehealth provider with Nebraska prescriptive authority, may write a prescription for compounded alprostadil that a 503A pharmacy can fill.

503A pharmacies compound alprostadil as an intracavernosal injection, often in a tri-mix or bi-mix combination with papaverine and phentolamine, or as a stand-alone preparation. Stand-alone compounded alprostadil at concentrations of 10 to 40 mcg/mL typically costs between $80 and $180 per vial depending on volume and pharmacy pricing, representing a substantial reduction from the $600 brand benchmark.

The Nebraska Board of Pharmacy licenses and inspects 503A compounding pharmacies operating within the state and recognizes out-of-state 503A pharmacies that hold non-resident pharmacy licenses. [6] Telehealth platforms that serve Nebraska patients may partner with licensed out-of-state 503As to ship compounded alprostadil directly to a Nebraska address, provided the originating prescription is valid and the pharmacy holds the appropriate Nebraska non-resident license.

503B outsourcing facilities, which produce compounded drugs in bulk without patient-specific prescriptions, operate under stricter FDA oversight. [6] Alprostadil compounded by a 503B facility for use in Nebraska must comply with FDA current good manufacturing practice standards and is typically distributed to clinics rather than directly to patients.

The FDA has not placed alprostadil on its list of drug substances that may not be compounded (the "negative list"), which means compounding remains permissible under current federal rules. [7] Patients should verify that any compounding pharmacy they use is registered with the Nebraska Board of Pharmacy before filling a prescription.

Which Insurance Plans Cover Alprostadil in Nebraska?

Most Nebraska commercial plans place alprostadil on a specialty or non-formulary tier, requiring prior authorization and step therapy. The specific coverage rules depend on the insurer and plan year.

Blue Cross Blue Shield of Nebraska lists injectable alprostadil as a covered benefit under some employer-sponsored plans but requires documentation of PDE5 inhibitor failure and a urologist or primary care note confirming organic erectile dysfunction. [8] Prior authorization approval typically takes 3 to 14 business days.

Medica, United Healthcare, and Aetna plans sold in Nebraska through the ACA marketplace generally apply the same step-therapy requirement. Out-of-pocket costs after prior authorization approval vary by plan, but co-pays for specialty-tier drugs typically range from $75 to $150 per fill for patients who have met their deductible.

Medicare Part D covers alprostadil on some formularies. The CMS Medicare Part D formulary lookup tool can confirm whether a specific plan in Nebraska covers Caverject or MUSE and at what tier. [9] Medicare Advantage plans with supplemental drug benefits follow Part D formulary rules and may have different tier placements.

Patients with employer-sponsored insurance should call the pharmacy benefits number on their insurance card before filling the first prescription and ask specifically whether a prior authorization form is needed and what clinical documentation is required.

How Does the Pfizer Savings Card Work in Nebraska?

The Pfizer savings card for Caverject is available to commercially insured patients in Nebraska and can reduce co-pays to as low as $25 per fill for eligible patients. The card does not apply to Medicare, Medicaid, or any government-funded insurance program. [10]

Enrollment is completed online at the Pfizer patient assistance portal. Once enrolled, a Nebraska patient presents the card at a participating pharmacy alongside their prescription. The card functions as a secondary payer, covering the gap between the patient's co-pay and a defined ceiling set by Pfizer's program terms.

The savings card does not reduce the cost for uninsured cash-pay patients. Those patients either pay full retail price, apply a GoodRx-type coupon, or pursue compounded alprostadil through a 503A pharmacy as outlined above.

Pfizer's RxPathways program provides free medication to uninsured or underinsured patients who meet income thresholds. [10] Nebraska patients who earn under 400% of the federal poverty level and lack prescription drug coverage may qualify for alprostadil at no cost through RxPathways. Applications require proof of income and a prescriber's attestation.

Can I Get Alprostadil via Telehealth in Nebraska?

Telehealth prescribing of alprostadil is permitted in Nebraska. The Nebraska Unicameral passed LB 894 in 2020, establishing a permanent telehealth framework that allows physicians, nurse practitioners, and physician assistants licensed in Nebraska to prescribe Schedule-appropriate medications after a synchronous audio-video encounter. [11] Alprostadil is not a controlled substance, so the telehealth prescribing rules for it are less restrictive than those for scheduled drugs.

A Nebraska telehealth provider may diagnose erectile dysfunction, review prior treatment history, and issue an alprostadil prescription during a single video visit. The provider must document the clinical basis for the diagnosis and confirm that either PDE5 inhibitor therapy has failed, is contraindicated, or is not preferred by the patient.

Prescriptions generated through a telehealth encounter in Nebraska can be sent electronically to any Nebraska-licensed retail pharmacy or to a licensed 503A compounding pharmacy. Many telehealth men's health platforms ship directly to patients in Omaha, Lincoln, Grand Island, Bellevue, and throughout rural Nebraska, reducing the need for in-person pharmacy visits.

What Is the Cheapest Way to Get Alprostadil in Nebraska?

The lowest out-of-pocket path for most Nebraska patients follows a three-step decision tree. First, check whether your commercial insurance will cover brand alprostadil after prior authorization. If approved and the Pfizer savings card applies, net cost can drop to $25 to $75 per fill. Second, if uninsured or if insurance denies coverage, apply to the Pfizer RxPathways program and to the NeedyMeds database, which lists additional Nebraska-specific patient assistance programs. [12] Third, if neither brand pathway is viable, obtain a prescription for compounded alprostadil from a telehealth provider and fill it at a Nebraska-licensed 503A pharmacy, where cost typically runs $80 to $180 per vial compared to the $600 brand benchmark.

Tri-mix (alprostadil plus papaverine plus phentolamine) compounded by a 503A pharmacy costs similarly and may be more effective for certain patients because the combination produces additive vasodilation through three distinct mechanisms. [13] Prescribers at HealthRX can write for either formulation depending on the patient's cardiovascular profile and response history.

Comparing prices across Nebraska pharmacies using the GoodRx or RxSaver tools before presenting a prescription is a simple step that can reduce brand costs by up to 15 percent at chains including Walgreens, CVS, and Walmart in Omaha and Lincoln. [3]

Clinical Background: How Alprostadil Works and Who Is a Candidate

Alprostadil binds to prostaglandin EP2 and EP3 receptors in corpus cavernosal smooth muscle, activating adenylyl cyclase and raising intracellular cyclic AMP. [14] The resulting smooth muscle relaxation dilates the helicine arteries, increases penile blood flow, and produces engorgement within 5 to 20 minutes. The effect is local and does not depend on sexual stimulation to the same degree as PDE5 inhibitors, which makes alprostadil particularly useful for men with severe arterial insufficiency or following radical prostatectomy.

The 1996 NEJM trial by Linet and colleagues remains the foundational efficacy reference. [1] In that multicenter, double-blind, placebo-controlled study of 296 men with chronic organic erectile dysfunction, 64.9% of alprostadil-treated men had at least one successful act of intercourse compared with 18.6% in the placebo group (P<0.001). [1] Penile pain was the most common adverse event, occurring in 10.9% of alprostadil recipients. Prolonged erection (priapism) occurred in 1% of patients and resolved with standard management. [1]

Contraindications include hypersensitivity to alprostadil, conditions predisposing to priapism (sickle cell anemia, multiple myeloma, leukemia), penile anatomical deformities, and use in sexual partners who are or may be pregnant (prostaglandin E1 can cause uterine contractions). The FDA label specifies a maximum dose of 60 mcg per injection for Caverject and 1 to 000 mcg per application for MUSE. [15]

The American Urological Association 2018 erectile dysfunction guideline states: "Vacuum erection devices, penile injections, intraurethral suppositories, and penile prostheses are effective treatments for ED and should be offered to patients." [2] That framing positions alprostadil as a clinically validated option, not a last resort, for men who have failed or prefer to avoid PDE5 inhibitors.

A 2018 Cochrane review of intracavernosal vasoactive agents (including prostaglandin E1 preparations) across 71 randomized controlled trials confirmed that alprostadil produces clinically significant improvement in erectile function scores compared to placebo, with a mean IIEF domain score improvement of approximately 5 to 8 points over baseline. [16]

Injection technique training is a standard part of initiating Caverject therapy. Nebraska prescribers, including those practicing via telehealth, typically schedule a training session (in-person or by video with supplemental written material) at the time of the first prescription. Proper technique reduces the risk of hematoma, nodule formation, and penile fibrosis associated with repeated injections. [15]

Nebraska-Specific Considerations for 2026

Nebraska has 93 counties, and pharmacy access varies significantly between the Omaha-Lincoln metro corridor and rural western Nebraska. Patients in rural counties such as Sioux, Dawes, or Cherry often face limited local pharmacy options. Telehealth prescribing combined with mail-order compounding pharmacies addresses this access gap directly because a licensed 503A can ship temperature-stable alprostadil preparations to any Nebraska ZIP code. [11]

Nebraska does not impose a state income tax on prescription drugs, so there is no additional tax burden on alprostadil purchases. The state also does not have a state-level prior authorization reform law that would shorten insurance timelines beyond ACA requirements, which means patients should budget 3 to 14 business days for commercial insurance approvals. [8]

Nebraska's 2024 legislative session did not modify the state pharmacy practice act in ways that affect 503A compounding eligibility, and the Nebraska Board of Pharmacy has not placed alprostadil on any state restricted-compounding list. Patients can confirm current licensed pharmacy status at the Nebraska Department of Health and Human Services credential verification portal. [6]

For patients starting alprostadil in 2026, the most cost-effective and accessible path in Nebraska typically involves a telehealth visit for prescribing, a check of commercial insurance prior authorization status, and a parallel inquiry to a licensed 503A pharmacy for compounded pricing, so the patient can compare total out-of-pocket cost before committing to a fill. [3] A starting dose of 2.5 mcg for Caverject is recommended by the FDA label for men with neurogenic erectile dysfunction, with titration to the lowest effective dose. [15]